Angiostatin, a recently discovered anti-angiogenic factor, offers the hope of long-term control of metastatic cancers following surgery.
The progression of a tumour from the benign to the malignant depends upon the acquisition of multiple genetic mutations within the cancer cells [1] . But one aspect that is common to the success of nearly every tumour's growth and dissemination is the absolute requirement of the expanding tumour to nourish itself. This is achieved by the promotion of angiogenesis, in which the growth of new capillaries is stimulated by means of the proliferation of endothelial cells within the tumour mass [2] . As well as providing the tumour with nutrients and oxygenation, the angiogenic competence of most primary tumours has the potentially lethal consequence of providing multiple access points through which metastatic tumour cells can reach the circulation. Angiogenesis is, therefore, an attractive target for therapeutic intervention, not least because it is not highly dependent upon cancer type or location.
Experimental models have shown that a solid tumour cannot grow larger than 1-2 mm in diameter without the induction of significant angiogenesis to supply its metabolic needs. In addition, recent studies have identified a range of angiogenic factors that are produced either by the tumour cells themselves or by tumour-associated cells, such as the surrounding fibroblasts or macrophages [2] . The relevance of such studies to clinical practice has been confirmed by the demonstration of a strong correlation between the number of microvessels detectable at the advancing front of the primary tumour and the incidence of metastatic disease in women with breast cancer [3] .
Several much more poorly characterized observations, however, suggest that tumours do not have things all their own way [1] . In particular, the presence of a primary tumour can sometimes inhibit the growth of its own metastases at distant sites, a phenomenon known as inhibition of (distant) tumour growth by tumour mass (Fig. 1) [4] . Thus, the metastases of some human cancers seem to proliferate much more rapidly following surgical removal of all or part of the primary tumour [5] . In addition, in certain animal models of cancer, a resistance to challenge with a secondary tumour can develop in animals that already bear a primary tumour, an effect that is dependent on the size of the primary tumour [4] . To explain such observations, imprecisely defined mechanisms have been proposed, in which the primary tumour either indirectly induces a vaccinating immunity to subsequent challenge (so-called concomitant immunity) [6] , or directly releases into the circulation unidentified antimitotic factors which restrain growth of the secondary metastases ( Fig. 1) [7] . Now, however, O'Reilly and colleagues from Judah Folkman's laboratory [8] have provided a molecular explanation by identifying a diffusible factor, released from a primary mouse tumour, which exerts a potent suppressive effect on the growth of metastases in the lungs.
The Boston group screened several murine tumour cell lines in a search for one in which the primary tumour that develops from the line inhibits the growth (but not the number) of its own metastases in the lungs. Of the cell lines screened, the 3LL Lewis lung carcinoma line, LLC-LM, was the most effective. LLC-LM lung metastases became highly neovascularized only after removal of the experimentally introduced primary subcutaneous tumour, and the cells within the metastases then showed a significant reduction in the level of apoptotic cell death compared to that in metastases growing in the presence of a primary tumour (Fig. 2a) . Having shown that the primary tumour can exert long-range growth control over secondary tumours, the activity responsible was identified as a circulating factor in the serum of primary tumour-bearing animals; it could both inhibit experimental vascularization and reduce the proliferation in vitro of several endothelial cell lines, but not of a range of tumour cells (Fig. 2b) .
The active component, purified from the serum as a 38 kD protein, was shown to be virtually identical to a 342 amino-acid internal fragment of plasminogen, a protease involved in the blood-clotting cascade. A similar fragment of human plasminogen strongly inhibited proliferation of endothelial cells in vitro, and could Molecular and biochemical characterization of angiostatin finally provides the framework for a credible working hypothesis to explain the inhibition of (distant) tumour growth by tumour mass. Angiostatin has a relatively long half-life in the mouse circulation (tA around 2.5 days), as compared to the brief existence of vascular endothelial growth factor (VEGF), the principal angiogenic potentiator of the 3LL tumour model. An established primary tumour that releases high levels of VEGF will, therefore, promote angiogenesis in its own vascular bed, but the levels of VEGF will fall off rapidly at distances away from the tumour. Conversely, even tumours that release only low levels of angiostatin locally will cause the build up of relatively high serum levels of the protein over time, inhibiting neovascularization of distant metastatic capillary beds. Removal of the primary tumour will remove the largest chronic source of angiogenic inhibitors so that, with time, angiogenesis will reappear in a metastasis as the balance of local stimulators (VEGF) and serum-borne inhibitors (angiostatin) swings in favour of metastatic growth.
If angiostatin is found to have a similar disease-controlling role in humans to that in the 3LL mouse model, it may help to provide both prognostic information and may even help directly in patient management (Fig. 3) .
The most life-threatening aspect of cancer is usually the development of metastases in vital organs. Often, a clinician will suspect the presence of occult metastases at the time of surgery but is powerless to prevent their development into lethal tumours. Surgery remains the best treatment option for most patients, to prevent the shedding of more metatstatically competent tumour cells into the circulation and, in some cases, early surgery will be curative (Fig. 4a) . Unfortunately, in the later stages of disease progression, the loss of the primary tumour might actually pose a real threat by causing the release of growth restraints on metastatic growth (Fig. 4) .
The justification for surgery cannot be doubted -the risk of metastasis is, after all, directly proportional to the number of cells that enter the circulation [9] . But effective anti-metastatic adjuvant therapy at the time of, and suppress the growth of 3LL lung metastases with an efficiency at least as high as that of a primary tumour (Fig. 2c) . Only the active fragment of plasminogen, and not the entire protein, was capable of reproducing the anti-metastatic activity. The authors [8] named the protein angiostatin, and confirmed that it is present in the serum of mice bearing primary 3LL tumours, and that its potent anti-angiogenic activity correlates well with the anti-proliferative activity of primary 3LL tumours on distant metastases. Fig. 3 . Theoretical uses of angiostatin.
to other types of therapies [10] , such as chemotherapy, radiotherapy, or even gene therapy, the beneficial effects of which would otherwise be swamped by the rapid development of metastatic growth following surgery.
The discovery of angiostatin may also help to explain another conundrum of cancer therapy, in which some patients -following apparently successful surgery -can suddenly develop aggressive, lethal recurrence of metastatic growths after periods of many years that are seemingly disease free. Why the tumour cells remain dormant for so long, and why they escape clearance, has not been satisfactorily explained. Perhaps the release of factor(s) such as angiostatin, initially by the primary tumour and then later by multiple micro-metastases, establishes sufficiently high systemic levels of anti-angiogenic factors to control metastatic growth over periods of years. Only when some perturbation of the system alters that fine balance can the secondary tumours expand, as a result of their now increased angiogenic potential. Screening patients who are currently in remission for alterations in levels of factors such as angiostatin may therefore provide clues as to the short-term course of latent disease. This information may help to predict imminent relapse and may provide cues for the prompt instigation of protective treatments aimed at controlling subsequent recurrences (Fig. 4c) .
The identification of angiostatin also adds one more member to the ever-growing list of potential tumour-suppressor (or, more accurately, metastasis-suppressor) proteins. Loss of function of the angiostatin gene may therefore be associated with a more aggressive progression of disease, and it may become possible to develop genetic screens that assess the integrity of the angiostatin gene in order to predict the likely severity of disease (Fig. 3) , although this possibility remains very speculative until much more work has been done with human patients. following, surgery might enhance patient survival in these particular cases (Fig. 4) , and this is where the experiments reported in the recent Cell paper [8] assume such potential significance for cancer treatment. If human angiostatin is found to be active against the growth of human metastases, long-term control of microscopic disease may be possible. The purification of therapeutic amounts of angiostatin may allow the benefits of surgery to be preserved, while the simultaneous administration of a metastasis-inhibiting drug would compensate for any adverse effects of the loss of the primary tumour (Fig.  4d ). Although such a treatment regimen is unlikely to cure the metastases, it may make control a realistic option. In this way, a tactical advantage may be afforded Not surprisingly, several questions remain unanswered, and it is important to maintain a realistic perspective on the significance of the discovery of angiostatin, particularly as it relates to the future therapy of human disease. For example, angiostatin is a new protein, the normal function of which has yet to be explained. As it is an internal fragment of plasminogen, it is possible that angiostatin is merely a fortuitous by-product of natural proteolytic cleavage reactions in vivo and that, of itself, it has no function beyond the particular experimental system in which it has been identified. Alternatively, the angiostatin fragment of plasminogen may have evolved for genuine physiological reasons. These might include providing a natural defence against cancer development, and/or a function in normal processes -such as termination of wound healing -in which a burst of angiogenesis must be terminated. The origins of the circulating angiostatin in tumour-bearing mice also remains a mystery. Many proteases are known to be released near invasive cancers, both by the tumour cells and by nearby activated fibroblasts, and these might be responsible for cleaving plasminogen into the active angiostatin species.
Alternatively, the tumour cells themselves may secrete plasminogen, or even angiostatin, directly.
As yet, angiostatin has been demonstrated to be effective in only one murine model system. Whether the molecule has any efficacy against, for example, human cell lines growing in athymic mice, let alone in patients, has yet to be shown. Excessive optimism based on control of experimental cancers in mice is a dangerous luxury. As a result of their extreme genetic plasticity, human tumour cells have a long and distinguished track record of evading promising therapeutic strategies. Indeed, repeated passage in mice of the 3LL tumour cells used to identify angiostatin eventually generated a variant in which growth of the primary tumour no longer protected against development of distant metastases [8] ; the emergence of human tumours that can evade any single antiangiogenic therapy is likely to be as swift within a patient. In addition, Folkman and colleagues [8] showed that other types of primary tumour are less effective in protecting the host from growth of metastases than Lewis lung carcinomas, so it seems likely that not all (if any) human cancers will be responsive to angiostatin-based therapies. Finally, a range of promising anti-angiogenic compounds are already in clinical trials [11] , and the results of these trials will give an indication of the efficacy of targeting tumour angiogenesis as a therapeutic strategy.
Despite these reservations, the prospect of a drug that confers long-term control over metastatic growth in situ is extremely appealing. The very near future should see answers to many of the questions that many cancer clinicians, constantly frustrated by an inability to control the insidious progression of metastatic lesions, will be asking about angiostatin. Screening patients for circulating levels of the molecule in vivo, demonstration of.its activity against angiogenesis in human tumours, and correlation with the course of human disease are no doubt well underway by now. The hope is that angiostatin will be able to make the transition from animal model to human patient with more success than many of its predecessors.
